Cure8 research brief
The study suggests that asymptomatic C. difficile colonization may not predict return of IBD activity in patients who are in remission, which could influence how clinicians interpret positive C. difficile tests in people without symptoms.
Adult patients with IBD in remission, gastroenterologists and IBD clinicians, and researchers studying the gut microbiome and infection-related triggers of flares.
This study followed 101 adults with IBD in clinical and biochemical remission, collecting serial stool samples (including culture and glutamate dehydrogenase and toxin testing) over a median 420 days. Baseline CDC prevalence was 13.9% and the incidence during follow-up was 8.2 per 100 person-years.
Using Cox regression, CDC was not associated with recurrence of IBD activity. The study is prospective and focused on patients in remission, which addresses a limitation of earlier work that mixed active and inactive disease. However, it was a single-center cohort with 101 participants, so results may not generalize to all settings.
Prospective design and repeated stool testing strengthen the finding, but the single-center setting and modest sample size limit generalizability. The article is presented as an abstract-based full-text; readers should consult the full paper for detailed methods and subgroup analyses.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
Achieving histologic or biochemical remission in addition to clinical and endoscopic remission was associated with substantially lower relapse risk in ulcerative colitis across multiple follow-up intervals, suggesting...
Early effective treatment may change long-term outcomes in Crohn's disease. Understanding the timing of a potential "window of opportunity" could affect decisions about when to start or escalate therapy.
